Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Anand Devaraj et al.|The Lancet Respiratory Medicine|2020Cited by 558
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trialMagdy Selim, Heena Olalde, Lydia D. Foster et al.|The Lancet Neurology|2019Cited by 249